Claims by Wyeth that its patented Prevnar 13 pneumococcal vaccine was inventive because other pharmaceutical giants had failed in developing similar vaccines are based on “hearsay and speculation,” Merck Sharp & Dohme told the court during closing submissions in the high-stakes trial over the world’s best-selling vaccine.
French pharmaceutical giant Sanofi has appealed a judge’s ruling denying its bid to block Alphapharm from listing an insulin injector pen on the Pharmaceutical Benefit Scheme.
A judge has denied Sanofi’s bid to block Alphapharm from listing its insulin injector pen on the Pharmaceutical Benefit Scheme, saying Sanofi has not established a strong enough case of infringement to justify granting the injunction.
Pharmaceutical giant Wyeth has accused Merck Sharp & Dohme of a “baseless” patent invalidity case, saying on the second day of trial over the world’s best selling vaccine that the development of its patented Prevnar 13 pneumococcal shot was anything but obvious, as its rival contends.
A showdown between global pharmaceutical giants over the world’s best selling vaccine began Monday in Federal Court, with Merck Sharp & Dohme claiming three patents for Prevnar 13 sold by Pfizer’s Wyeth are invalid and that its own vaccine offers greater protection against pneumococcal bacteria.
Keyboard specialist PKT Technologies has returned for an encore in a six-year long trade mark dispute, appealing a $384,000 judgment against it for violating a trade mark licence agreement with engineer Peter Vogel, inventor of the groundbreaking synthesiser behind some of 80s pop music’s most iconic sounds.
Generic drug maker Alphapharm says rival Sanofi-Aventis waited to amend its injector pen patent until the heated IP battle between the two firms had commenced, despite knowing about the amendments for three years.
Generic drug maker Alphapharm has lost another bid for documents from Sanofi-Aventis in advance of a hearing on Sanofi’s interlocutory application seeking to block the generic drug maker from listing its injector pen on the Pharmaceutical Benefits Scheme.
A four-day trial against online ticket reseller Viagogo kicked off Monday, with the ACCC describing how the site misled consumers by falsely claiming it was an official ticket vendor, hitting them with a booking fee of around 28 per cent along the way.
A group representing patent and trade mark lawyers is seeking to intervene in a high-stakes appeal over computer software patents.